3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
1461
Pancreatic Neoplasms
832
Stomach Neoplasms
692
Carcinoma, Hepatocellular
647
Carcinoma, Non-Small-Cell Lung
540
Neoplasms
459
Breast Neoplasms
369
Ovarian Neoplasms
338
Neoplasm Metastasis
336
Colonic Neoplasms
331
Esophageal Neoplasms
297
Liver Neoplasms
265
Melanoma
255
Lung Neoplasms
245
Squamous Cell Carcinoma of Head and Neck
210
Cholangiocarcinoma
180
Carcinoma, Renal Cell
180
Prostatic Neoplasms
175
Head and Neck Neoplasms
172
Triple Negative Breast Neoplasms
162
Endometrial Neoplasms
160
Rectal Neoplasms
159
Uterine Cervical Neoplasms
155
Gastrointestinal Neoplasms
142
Urinary Bladder Neoplasms
139
Biliary Tract Neoplasms
135
Gastrointestinal Stromal Tumors
108
Sarcoma
104
Esophageal Squamous Cell Carcinoma
102
Small Cell Lung Carcinoma
95
Interventions
Ramucirumab
1
Fluorouracil
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Gastric Adenocarcinoma
×
Gastrointestinal
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts